CFTR and cystic fibrosis: Genetically defined and patient-derived tissue-specific in vitro models of CF continue to be highly relevant to find suitable treatments for the remaining ~10–18% of people with CF who will not benefit from current CFTR-directed drug treatments [15,16,17], in order to assess personalised CFTR modulator responses and investigate non-lung CF symptoms [18,19,20].